About Lysosomal-associated transmembrane protein 4B
Lysosomal-associated transmembrane protein 4B (LAPTM4B) is a protein
from Homo sapiens identified by UniProt accession
Q86VI4, 317 residues long.
MolForge cross-references it against 0 known binders and
110 disease associations.
Target properties
| Protein name | Lysosomal-associated transmembrane protein 4B |
|---|
| UniProt accession | Q86VI4 |
|---|
| Gene | LAPTM4B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 317 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (110)
Diseases linked to this target (Open Targets).
- calcium measurement · score 0.41
- QT interval · score 0.29
- drug use measurement · score 0.27
- arterial stiffness measurement · score 0.12
- hepatocellular carcinoma · score 0.11
- neoplasm · score 0.10
- cancer · score 0.10
- mean corpuscular hemoglobin · score 0.10
- non-small cell lung carcinoma · score 0.10
- mean corpuscular volume · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q86VI4-F1 | alphafold | PREDICTED | 63.77 | — |
Amino-acid sequence (317 residues)
MTSRTRVTWP SPPRPLPVPA AAAVAFGAKG TDPAEARSSR GIEEAGPRAH GRAGREPERR RSRQQRRGGL QARRSTLLKT CARARATAPG AMKMVAPWTR FYSNSCCLCC HVRTGTILLG VWYLIINAVV LLILLSALAD PDQYNFSSSE LGGDFEFMDD ANMCIAIAIS LLMILICAMA TYGAYKQRAA WIIPFFCYQI FDFALNMLVA ITVLIYPNSI QEYIRQLPPN FPYRDDVMSV NPTCLVLIIL LFISIILTFK GYLISCVWNC YRYINGRNSS DVLVYVTSND TTVLLPPYDD ATVNGAAKEP PPPYVSA
Explore Lysosomal-associated transmembrane protein 4B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets